Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$8.33 USD
+0.37 (4.65%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $8.34 +0.01 (0.12%) 6:48 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Iovance Biotherapeutics (IOVA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$25.58 | $34.00 | $19.00 | 221.36% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Iovance Biotherapeutics comes to $25.58. The forecasts range from a low of $19.00 to a high of $34.00. The average price target represents an increase of 221.36% from the last closing price of $7.96.
Analyst Price Targets (12)
Broker Rating
Iovance Biotherapeutics currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, 13 are Strong Buy, representing 92.86% of all recommendations. A month ago, Strong Buy represented 92.86%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 13 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.14 | 1.14 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/20/2024 | JMP Securities | Reni Benjamin | Strong Buy | Strong Buy |
6/3/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
3/14/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
3/7/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
3/1/2024 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Strong Buy |
2/29/2024 | Goldman Sachs | Andrea Tan | Strong Buy | Strong Buy |
2/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/20/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
2/19/2024 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
10/2/2023 | Guggenheim Securities | Kelsey Goodwin | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 14 |
Average Target Price | $25.58 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.37 |